Kaiser Permanente-backed respiratory device provider Vapotherm floated at the bottom of its range but raised $56m in its initial public offering.

Merck & Co, AstraZeneca and Alexion are all in line for exits after Moderna Therapeutics, valued at $7.5bn earlier this year, filed for its initial public offering.

The Tencent, Bertelsmann and Ping An-backed owner of social commerce platform Mogujie is looking to raise $200m in the offering.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.

UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.

Novartis and Access Industries were among the investors that bought $37.5m of the shares, which the cell therapy developer issued at a downgraded price.

Qualcomm-backed video conferencing platform Zoom is gearing up for an initial public offering that would reportedly value the company at several billion dollars.